PROTHENA CORP PLC (PRTA) Fundamental Analysis & Valuation

NASDAQ:PRTA • IE00B91XRN20

9.59 USD
+0.13 (+1.37%)
At close: Mar 6, 2026
9.59 USD
0 (0%)
After Hours: 3/6/2026, 4:20:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PRTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

PRTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. PRTA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PRTA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. PRTA Profitability Analysis

1.1 Basic Checks

  • PRTA had negative earnings in the past year.
  • PRTA had a negative operating cash flow in the past year.
  • PRTA had negative earnings in 4 of the past 5 years.
  • In the past 5 years PRTA reported 4 times negative operating cash flow.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • The Return On Assets of PRTA (-79.53%) is worse than 67.12% of its industry peers.
  • The Return On Equity of PRTA (-95.07%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROIC N/A
ROA(3y)-39.39%
ROA(5y)-24.52%
ROE(3y)-46.11%
ROE(5y)-28.55%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • PRTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PRTA Health Analysis

2.1 Basic Checks

  • PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PRTA has about the same amount of shares outstanding.
  • PRTA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • PRTA has an Altman-Z score of -1.02. This is a bad value and indicates that PRTA is not financially healthy and even has some risk of bankruptcy.
  • PRTA has a Altman-Z score of -1.02. This is comparable to the rest of the industry: PRTA outperforms 55.19% of its industry peers.
  • PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.02
ROIC/WACCN/A
WACC7.7%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.61 indicates that PRTA has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.61, PRTA is doing good in the industry, outperforming 67.31% of the companies in the same industry.
  • A Quick Ratio of 6.61 indicates that PRTA has no problem at all paying its short term obligations.
  • PRTA has a Quick ratio of 6.61. This is in the better half of the industry: PRTA outperforms 67.88% of its industry peers.
Industry RankSector Rank
Current Ratio 6.61
Quick Ratio 6.61
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PRTA Growth Analysis

3.1 Past

  • PRTA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.87%.
  • The Revenue for PRTA has decreased by -92.83% in the past year. This is quite bad
  • Measured over the past years, PRTA shows a very strong growth in Revenue. The Revenue has been growing by 60.83% on average per year.
EPS 1Y (TTM)-70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.96%
Revenue 1Y (TTM)-92.83%
Revenue growth 3Y-43.57%
Revenue growth 5Y60.83%
Sales Q2Q%-99.01%

3.2 Future

  • Based on estimates for the next years, PRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.02% on average per year.
  • The Revenue is expected to grow by 88.83% on average over the next years. This is a very strong growth
EPS Next Y115.46%
EPS Next 2Y33.17%
EPS Next 3Y25.53%
EPS Next 5Y22.02%
Revenue Next Year1183.79%
Revenue Next 2Y73.59%
Revenue Next 3Y109.06%
Revenue Next 5Y88.83%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

3

4. PRTA Valuation Analysis

4.1 Price/Earnings Ratio

  • PRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 15.78, the valuation of PRTA can be described as correct.
  • Based on the Price/Forward Earnings ratio, PRTA is valued cheaply inside the industry as 96.15% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.79. PRTA is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 15.78
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PRTA's earnings are expected to grow with 25.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.17%
EPS Next 3Y25.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRTA Dividend Analysis

5.1 Amount

  • PRTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRTA Fundamentals: All Metrics, Ratios and Statistics

PROTHENA CORP PLC

NASDAQ:PRTA (3/6/2026, 4:20:24 PM)

After market: 9.59 0 (0%)

9.59

+0.13 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-06
Inst Owners79.92%
Inst Owner Change9.22%
Ins Owners19.38%
Ins Owner Change0%
Market Cap516.23M
Revenue(TTM)9.68M
Net Income(TTM)-280.46M
Analysts75.38
Price Target20.91 (118.04%)
Short Float %16.32%
Short Ratio12.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.94%
Min EPS beat(2)-28.86%
Max EPS beat(2)2.98%
EPS beat(4)1
Avg EPS beat(4)-10.08%
Min EPS beat(4)-28.86%
Max EPS beat(4)2.98%
EPS beat(8)3
Avg EPS beat(8)21.35%
EPS beat(12)6
Avg EPS beat(12)43.16%
EPS beat(16)6
Avg EPS beat(16)21.31%
Revenue beat(2)0
Avg Revenue beat(2)-41.76%
Min Revenue beat(2)-64.33%
Max Revenue beat(2)-19.2%
Revenue beat(4)0
Avg Revenue beat(4)-52.91%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-19.2%
Revenue beat(8)1
Avg Revenue beat(8)86.12%
Revenue beat(12)3
Avg Revenue beat(12)64.36%
Revenue beat(16)3
Avg Revenue beat(16)25.69%
PT rev (1m)0.82%
PT rev (3m)11.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.06%
EPS NY rev (1m)0%
EPS NY rev (3m)505.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.78
P/S 43.8
P/FCF N/A
P/OCF N/A
P/B 1.75
P/tB 1.75
EV/EBITDA N/A
EPS(TTM)-3.93
EYN/A
EPS(NY)0.61
Fwd EY6.34%
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0.22
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.39%
ROA(5y)-24.52%
ROE(3y)-46.11%
ROE(5y)-28.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.16%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.61
Quick Ratio 6.61
Altman-Z -1.02
F-Score3
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.96%
EPS Next Y115.46%
EPS Next 2Y33.17%
EPS Next 3Y25.53%
EPS Next 5Y22.02%
Revenue 1Y (TTM)-92.83%
Revenue growth 3Y-43.57%
Revenue growth 5Y60.83%
Sales Q2Q%-99.01%
Revenue Next Year1183.79%
Revenue Next 2Y73.59%
Revenue Next 3Y109.06%
Revenue Next 5Y88.83%
EBIT growth 1Y-32.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.67%
OCF growth 3YN/A
OCF growth 5YN/A

PROTHENA CORP PLC / PRTA FAQ

What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRTA.


What is the valuation status for PRTA stock?

ChartMill assigns a valuation rating of 3 / 10 to PROTHENA CORP PLC (PRTA). This can be considered as Overvalued.


What is the profitability of PRTA stock?

PROTHENA CORP PLC (PRTA) has a profitability rating of 0 / 10.